Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: Propagermanium in FSGS
NCT03649152Phase 2Completed
- Sponsor
- Dimerix
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of repagermanium in focal segmental glomerulosclerosis (FSGS), sponsored by Dimerix. Started Nov 2018; status: completed.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03649152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649152.